PT  - JOURNAL ARTICLE
AU  - Yu, Mengyao
AU  - Harper, Andrew R.
AU  - Aguirre, Matthew
AU  - Pittman, Maureen
AU  - Tcheandjieu, Catherine
AU  - Amgalan, Dulguun
AU  - Grace, Christopher
AU  - Goel, Anuj
AU  - Farrall, Martin
AU  - Xiao, Ke
AU  - Engreitz, Jesse
AU  - Pollard, Katherine
AU  - Watkins, Hugh
AU  - Priest, James R.
TI  - Genetic determinants of interventricular septal anatomy and the risk of ventricular septal defects and hypertrophic cardiomyopathy
AID  - 10.1101/2021.04.19.21255650
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.19.21255650
4099  - http://medrxiv.org/content/early/2021/04/22/2021.04.19.21255650.short
4100  - http://medrxiv.org/content/early/2021/04/22/2021.04.19.21255650.full
AB  - Background The interventricular septum (IVS) plays a primary role in cardiovascular physiology and a large proportion of genetic risk remains unexplained for structural heart disease involving the IVS such as hypertrophic cardiomyopathy (HCM) and ventricular septal defects (VSD).Objectives We sought to develop a reproducible proxy of IVS structure from standard medical imaging, discover novel genetic determinants of IVS structure, and relate these loci to two rare diseases of the IVS.Methods We performed machine learning to estimate the cross-sectional area of the interventricular septum (IVS.csad) obtained from the 4-chamber view of cardiac MRI in 32,219 individuals from the UK Biobank. Using these extracted measurement of IVS.csad we performed phenome-wide association to relate this proxy measure to relevant clinical phenotypes, followed by genome-wide association studies and Mendelian Randomization.Results Automated measures of IVS.csad were highly accurate, and strongly correlated with anthropometric measures, blood pressure, and diagnostic codes related to cardiovascular physiology. A Single nucleotide polymorphism in the intron of CDKN1A was associated with IVS.csad (rs2376620, Beta 8.4 mm2, 95% confidence intervals (CI) 5.8 to 11.0, p=2.0e-10), and a common inversion incorporating KANSL1 predicted to disrupt local chromatin structure was associated with an increase in IVS.csad (Beta 8.6 mm2, 95% CI 6.3-10.9, p=1.3e-13). Mendelian Randomization suggested that inheritance of a larger IVS.csad was causal for HCM (Beta 2.45 log odds ratio (OR) HCM per increase in SD of IVS.csad, standard error (SE) 0.48, pIVW = 2.8e-7) while inheritance of a smaller IVS.csad was causal for VSD (Beta −2.06 log odds ratio (OR) VSD per decrease in SD of IVS.csad, SE 0.75, pIVW = 0.006)Conclusion Automated derivation of the cross sectional area of the IVS from the 4-chamber view allowed discovery of loci mapping to genes related to cardiac development and Mendelian disease. Inheritance of a genetic liability for either large or small interventricular septum, appears to confer risk for HCM or VSD respectively, which suggests that a considerable proportion of risk for structural and congenital heart disease may be localized to the common genetic determinants of cardiovascular anatomy.Competing Interest StatementDr. Priest is an employee and shareholder of Tenaya Therapeutics which has publicly disclosed development programs in Hypertrophic Cardiomyopathy. Dr. Watkins is a paid consultant to BioMarin Dr. Harper is an employee of AstraZenecaFunding StatementNo authors or institutions received payment or services from a third party for any aspect of the submitted work. JRP has been supported by the National Heart Lung and Blood Institute (R00 HL130523) and Chan-Zuckerberg Biohub.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The NHS National Research Ethics Service (ref: 11/NW/0382) granted ethical approval for the distribution of deidentified imaging, genetic, and medical record data from the UK Biobank (UKB) for any qualified researcher.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available from the UK Biobank organization.